 Rebimastat was used in a Paclitaxel/Carboplatin treatment in phase III.The results of the trial was a higher incidence of adverse reactions, without survival benefit.Clinical trials for Tanomastat, an alfa-((phenylthio)methyl)carboxylate, showed similar results.